

FOC20" 5042T660




Fig. 1-A

FO220" E042T660




Fig. 1-B

FO2220-50421650




Fig. 1-C

FOU220-ED4ZT650

Size : 0.6360 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN




Fig. 2-A

Size: 1.7840 mg
 Method: 10 DEG C/MIN AMB TO 300
 Comment: SEALED PAN




Fig. 2-B

FO2220-EDH27660

Size: 1.4230 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN




Fig. 2-C

FD220" ECH2F650

Size: 1.0400 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN




Fig. 2-D

FD-220" E042F650

Sample Weight: 15.300 mg
 Comment: N-Propyl Alcohol solvate 1
 unsealed pan




Fig. 2-E

TO220" E042T660




Fig. 3-A

FOZ220" 504ZF650




Fig. 3-B

102220-EOH2T660




Fig. 3-C

10220" ETH/F60




Fig. 3-D

TO2220" E044T660




Fig. 4

FOZ20" EOHZT660




Fig. 5




Fig. 6-A

FOC220" EDH42T660




Fig. 7

FD220-0047650




Fig. 8

TO220-5042F50




Fig. 9

FD4220" ECH/TE60




Fig. 10




Fig. 11




Fig. 12

FD2220" E04/T660




Fig. 13




Fig. 14




Fig. 15





Fig. 16



Interaction of A: Cooling Rate and B: Purity

Fig. 17






Fig. 18



Form

A: Cooling Rate
B: Purity
C: End Point

Fig. 19



Interaction of B: Purity and C: End Point

Fig. 20

10/22/07 10:47:16




Fig. 21

10/22/01 10:47:16




Fig. 22

Fig. 23
Study Schematic





Fig. 24
Baseline Demographics

BB		
	Pbo (N = 66)	Epi (N = 69)
Mean Age (Yrs.)	58.7	55.4
Gender [N (%)]		
Female	37 (56.1)	34 (49.3)
Male	29 (43.9)	35 (50.7)
Ethnicity [N (%)]		
Asian	0 (0.0)	1 (1.4)
Black	0 (0.0)	1 (1.4)
Caucasian	65 (98.5)	67 (97.1)
Other	1 (1.5)	0 (0.0)

Fig. 25
Baseline Weight, BP, Heart Rate


	BB	
Mean Values	Pbo (N = 66)	Epl (N = 69)
Weight (kg)		
Female	70.4	82.0
Male	88.9	84.2
BP (mmHg)		
SBP / DBP	157.2 / 98.8	158.2 / 99.0
Heart Rate (bpm)	65.7	68.7

Fig. 26
Mean Change From Baseline in BP
Week 8 (Final Visit)



*Adjusted to treatment, center, and baseline value

Fig. 27
Mean Change in BP (Each Visit):
BB and Eplerenone



*Adjusted to treatment, center, and baseline value

Fig. 28
Active Renin and Aldosterone:
BB and Eplerenone




Fig. 29
Adverse Events

Adverse Events	BB	
	Pbo (N = 66)	Epl (N = 69)
Hyp rkalemia	0	4*
Hyperuricemia	0	0
Increased Lab Values		
GGT	0	0
SGOT	0	0
SGPT	0	0
BUN	0	0
Impotence	0	0
Gynecomastia	0	0
Hypotension	0	0
M nstrual Irregularities	0	0

* 3 cases of hyperkalemia resolved spontaneously with continued treatment, and one patient was withdrawn